doi: 10.1161/01.RES.0000141774.29937.e3
© 2004 American Heart Association, Inc.
Reviews |
Nuclear Receptor Signaling and Cardiac Energetics
From the Center for Cardiovascular Research and Departments of Medicine (J.M.H., D.P.K.), Molecular Biology and Pharmacology (D.P.K.), and Pediatrics (D.P.K.), Washington University School of Medicine, St Louis, Mo.
Correspondence to Daniel P. Kelly, MD, Center for Cardiovascular Research Washington University School of Medicine, St. Louis, MO 63110. E-mail dkelly{at}im.wustl.edu
This Review is part of a thematic series on Nuclear Receptor Signaling, which includes the following articles:
Nuclear Receptor Signaling and Cardiac Energetics
PPARs and Atherogenesis: Regulators of Gene Expression in Vascular Cells
Nuclear Receptor Signaling in the Control of Cholesterol Homeostasis
Daniel Kelly Guest Editor
 |
Abstract |
|---|
 Top Abstract IntroductionNuclear Receptors: A Brief...PPARs: Regulators of Cardiac...PGC-1 Family: Inducible NR...Estrogen-Related Receptors:...Altered NR Signaling in...Future DirectionsReferences |
|---|
The heart has a tremendous capacity for ATP generation, allowing it to function as an efficient pump throughout the life of the organism. The adult myocardium uses either fatty acid or glucose oxidation as its main energy source. Under normal conditions, the adult heart derives most of its energy through oxidation of fatty acids in mitochondria. However, the myocardium has a remarkable ability to switch between carbohydrate and fat fuel sources so that ATP production is maintained at a constant rate in diverse physiological and dietary conditions. This fuel selection flexibility is important for normal cardiac function. Although cardiac energy conversion capacity and metabolic flux is modulated at many levels, an important mechanism of regulation occurs at the level of gene expression. The expression of genes involved in multiple energy transduction pathways is dynamically regulated in response to developmental, physiological, and pathophysiological cues. This review is focused on gene transcription pathways involved in short- and long-term regulation of myocardial energy metabolism. Much of our knowledge about cardiac metabolic regulation comes from studies focused on mitochondrial fatty acid oxidation. The genes involved in this key energy metabolic pathway are transcriptionally regulated by members of the nuclear receptor superfamily, specifically the fatty acid-activated peroxisome proliferator-activated receptors (PPARs) and the nuclear receptor coactivator, PPAR
coactivator-1
(PGC-1). The dynamic regulation of the cardiac PPAR/PGC-1 complex in accordance with physiological and pathophysiological states will be described.
Key Words: mitochondria • fatty acids • peroxisome proliferator-activated receptor • gene regulation • PPAR
|
Introduction |
|---|
|
TopAbstractIntroductionNuclear Receptors: A Brief...PPARs: Regulators of Cardiac...PGC-1 Family: Inducible NR...Estrogen-Related Receptors:...Altered NR Signaling in...Future DirectionsReferences |
|---|
The normal adult heart uses two main energy substrates, fatty acids (FA) and glucose, to generate ATP for cardiac work.1,2 The major "work" functions of the cardiac myocyte are contraction (pump function), Ca2+ uptake into the sarcoplasmic reticulum, and maintenance of the sarcolemmal ion gradients. Under normal conditions, nearly all of the ATP is generated from mitochondrial oxidation of FA and glucose; 2% or less is derived from anaerobic glycolysis. FA oxidation (FAO) supplies 60% to 90% of myocardial ATP in the healthy adult mammalian heart, whereas the balance (10% to 40%) comes from glucose and lactate3–5 (Figure 1). FAs are catabolized in the mitochondrial matrix by the process of ß-oxidation, whereas pyruvate derived from glucose and lactate is oxidized by the pyruvate dehydrogenase (PDH) complex, localized within the inner mitochondrial membrane. Acetyl-CoA derived from both pathways is oxidized by the tricarboxylic acid (TCA) cycle to generate NADH and FADH2, which are used by the electron transport chain to establish a proton gradient that when coupled to oxidative phosphorylation drives ATP formation.
|
Although FAO serves as the primary myocardial ATP-generating pathway, the heart has relatively limited lipid storage capacity. Thus, the pathways of cellular FA uptake and oxidation must be tightly coupled. Uptake of long-chain FAs (LCFAs) into cells is facilitated by the transport proteins, FA transport protein 1 (FATP1), and CD36/FAT.6,7 LCFA uptake is coupled to esterification by fatty acyl-CoA synthetase (FACS).6 The resulting long-chain acyl-CoAs are converted by carnitine palmitoyltransferase I (CPT I) to their carnitine derivatives, which are transported into the mitochondria and enter the ß-oxidation pathway (Figure 1).
Myocardial fuel selection is highly influenced by developmental stage and physiological/pathophysiological conditions (see review2). Much of this regulation is achieved by coordinated changes in the expression of genes involved in cellular FA utilization. For example, a switch in cardiac fuel preference from glucose to FAs occurs during the fetal to newborn transition when O2 availability and dietary fat content abruptly increase.8,9 The expression of genes encoding enzymes of FA uptake and mitochondrial ß-oxidation is coordinately increased in parallel with this perinatal energy substrate switch. The critical importance of this metabolic switch in postnatal adaptation is evidenced in children with mutations in the FA ß-oxidation enzyme genes, MCAD and VLCAD, who develop hepatic dysfunction and cardiomyopathy during the postnatal period under conditions of illness or metabolic stress.10–12 Acquired forms of heart failure are also associated with energy substrate "switches." In pressure- or volume overload-induced hypertrophy, mitochondrial oxidative capacity is reduced and the heart shifts to reliance on glucose metabolism, resembling the fetal metabolic program.13–16 Conversely, in the uncontrolled diabetic state, because of the combined effects of myocyte insulin resistance and high circulating free FAs, the myocardium uses fats almost exclusively to support ATP synthesis.17,18 In these disease states, the profile of metabolic gene expression parallels the metabolic shift; thus expression of ß-oxidation genes are downregulated in the hypertrophied heart and induced in the diabetic state.14,19,20
|
Nuclear Receptors: A Brief Primer |
|---|
|
TopAbstractIntroductionNuclear Receptors: A Brief...PPARs: Regulators of Cardiac...PGC-1 Family: Inducible NR...Estrogen-Related Receptors:...Altered NR Signaling in...Future DirectionsReferences |
|---|
Nuclear receptor (NR) transcription factors are particularly well-suited for regulating the cardiac metabolic gene program. NRs were originally described as ligand-dependent transcription factors, which is the case for roughly half the mammalian NRs.21 Ligand-activated receptors include the classical endocrine receptors that respond to steroid hormones or thyroid hormone. In recent years, a number of receptors identified without prior insight to their ligands have been shown to respond to dietary-derived lipid intermediates, including long-chain FAs, oxysterols, and bile acids.22–24 These receptors are generally involved in feed-forward regulation of pathways involved in the metabolism of these activating ligands. The remaining "orphan" NRs have no identified ligands, although it is likely that modulating ligands will be identified for some of these receptors. Because the heart must adapt to continuously changing energy demands but has limited capacity for storing FAs or glucose, myocardial energy substrate flux must be tightly matched with demand. Ligand-activated NRs are poised to rapidly respond to fluctuating substrate levels. As will be described later, the peroxisome proliferator-activated receptors (PPARs), as FA-activated NRs, are now recognized as key regulators of cardiac FA metabolism. In addition, evidence is emerging that a select group of orphan NRs serve novel roles in regulating cardiac energy metabolism.
NRs have a conserved modular domain structure (Figure 2A). These proteins contain an NH2-terminal ligand-independent transcriptional activation (AF-1) domain, a conserved zinc-finger DNA binding domain (DBD), and a composite COOH-terminal region that includes the ligand binding domain (LBD) and a conserved ligand-dependent activation function (AF-2). NRs bind to regulatory DNA elements in target genes as homodimers, heterodimers, or in some cases as monomers. Unlike the classic steroid receptors that function as homodimers, many of the NRs involved in nutrient sensing and metabolic regulation heterodimerize with the retinoid X receptor (RXR).23 NR regulatory DNA elements are composed of variably spaced hexameric half-sites (AGGTCA) arranged as direct, indirect, or everted repeats. Once bound to their specific response element, receptors recruit coactivator proteins often coincident with displacement of corepressor proteins (Figure 2B). For ligand-activated receptors, it is through ligand binding that the LBD adopts a permissive conformation for coactivator interaction. More than 100 coactivator proteins have been identified for NRs, including ATP-dependent chromatin remodeling complexes, histone acetylases, histone methyltransferases, and RNA polymerase II recruiting complexes, that open up the chromatin structure and facilitate binding of basal transcription factors and RNA polymerase II.25 Histone-modifying proteins are often recruited into complexes by adapter proteins, which lack catalytic activity, bound to the NR LBD. One such adapter/coactivator, the PPAR coactivator-1 (PGC-1), serves as a key link between physiological cues and metabolic regulation in heart.
|
|
PPARs: Regulators of Cardiac FA Metabolism |
|---|
|
TopAbstractIntroductionNuclear Receptors: A Brief...PPARs: Regulators of Cardiac...PGC-1 Family: Inducible NR...Estrogen-Related Receptors:...Altered NR Signaling in...Future DirectionsReferences |
|---|
The peroxisome proliferator-activated receptors (PPAR) are involved in various aspects of lipid metabolism.26,27 Three PPAR isoforms have been identified: PPAR
, PPARß/
(hereafter PPARß), and PPAR. All three PPARs are activated by FAs and bind as obligate heterodimers with RXR to the consensus response element, AGGTCANAGGTCA (direct repeat with a single nucleotide spacing), within the regulatory regions of target genes. Functional specificity among the PPARs is achieved by isoform-specific tissue distribution, ligands, and cofactor interactions.28,29 PPAR has been characterized as the central regulator of mitochondrial FA catabolism, whereas PPAR is thought to primarily regulate lipid storage. Until recently, the function of PPARß was relatively unexplored. However, several lines of evidence suggest that all three isoforms modulate cardiac energy metabolism.
PPAR
PPAR is thought to be the primary transcriptional regulator of fat metabolism in tissues with high FA oxidation rates, such as heart, liver, kidney, and skeletal muscle.30 Although the endogenous ligand for PPAR has not been identified, PPAR is activated by a number of lipid-derived molecules, including long-chain FAs, eicosanoids, and leukotriene B4.31,32 The fibrate class of hyperlipidemic drugs, including fenofibrate and gemfibrozil, are synthetic PPAR ligands.31 In studies using gain- and loss-of-function strategies, genetically altered mice have shown that PPAR regulates genes involved in virtually every step of cardiac FA utilization including (1) FA uptake, (2) thioesterification to fatty acyl-CoA, (3) transport into the mitochondria, and (4) mitochondrial ß-oxidation (Figure 1 and Table). The gene encoding medium-chain acyl-CoA dehydrogenase (MCAD), which catalyzes the first step in the ß-oxidation pathway, was the first energy metabolic target identified for PPAR.33 The complex response element (NRRE-1) conferring PPAR responsiveness binds several NRs and dictates the developmental and FA responsiveness of the MCAD gene.34
|
Definitive evidence for PPAR as a key regulator of cardiac energy metabolism has been provided by the PPAR "knockout" (PPAR–/–) mouse studies.35,36 Constitutive expression of genes involved in FA uptake (CD36/FAT, FATP, FACS-1), mitochondrial transport (CPT I, CPT II), and ß-oxidation (MCAD, VLCAD, SCAD, SCHAD, trifunctional protein ) are decreased in hearts of PPAR–/– mice.37,38 Correspondingly, myocardial long chain FA uptake and oxidation rates are diminished in PPAR–/– hearts.37,39 Despite these metabolic derangements, cardiac function is maintained in unstressed adult animals. However, a fasting stress, which in wild-type mice induces cardiac ß-oxidation enzyme gene expression,40,41 causes hypoglycemia and hepatic and cardiac triglyceride accumulation in PPAR–/– mice.40 With aging, PPAR–/– mice develop cardiac fibrosis and myofibrillar fragmentation associated with abnormal mitochondrial ultrastructure.37
Murine PPAR gain-of-function strategies have also provided important evidence for the role of PPAR as a direct regulator of myocardial energy metabolic genes. Cardiac-specific PPAR overexpression (MHC-PPAR mice) activates expression of FA utilization genes.20 Metabolic studies showed that FA uptake and oxidation are increased in MHC-PPAR hearts, whereas glucose utilization is reciprocally decreased.20,42 Diminished glucose utilization is explained, in part, by well-described inhibitory effects of acetyl-CoA/CoASH, ATP/ADP, and NADH/NAD+ ratios, increased during high rates of FA oxidation, on the activity of the PDH complex.43,44 However, the reciprocal reduction in myocardial glucose oxidation in MHC-PPAR mice also involves gene regulatory effects. Expression of pyruvate dehydrogenase kinase 4 (PDK4), which decreases glucose oxidation through PDH inhibition, is markedly induced in MHC-PPAR hearts. In addition, the glucose transporter, GLUT4, and the glycolytic enzyme phosphofructokinase are downregulated in MHC-PPAR hearts.20 These results suggest that PPAR links circuits involved in reciprocal gene regulatory "crosstalk" between myocardial FA and glucose utilization. Collectively, the results of in vivo studies indicate that PPAR activates expression of genes involved in cardiac FA utilization and mediates dynamic metabolic regulation in response to diverse physiological stimuli allowing the heart to meet energy demands and maintain tight lipid balance.
PPARß: An Emerging Player in the Regulation of Cardiac Energetics
Among the PPAR isoforms, PPARß displays an expression pattern least suggestive of a distinct role in lipid metabolism. It is detectable in numerous cell types within all major organ systems, in contrast to PPAR and PPAR, which are highly expressed in fat utilization or fat storage tissues, respectively.28,29,45 However, PPARß is activated by FAs and the triglyceride component of VLDL particles implicating this NR in the regulation of lipid metabolism.46,47 Independent analyses of PPARß–/– gene deletion have revealed varied phenotypic effects in skin, adipose, placenta formation and brain.48–50 Notably, one line of PPARß–/– mice was deficient in brown and white adipose formation, supporting a role for PPARß in lipid homeostasis.49
Gain-of-function studies involving PPARß overexpression or treatment with selective PPARß agonists have demonstrated a role for PPARß in regulating expression of FA utilization enzymes and increasing FAO rates in skeletal muscle cells.51–53 Activation of the PPARß regulatory pathway in vivo has been shown to increase lipid catabolism when ectopically expressed white adipose,54 to enrich slow-twitch oxidative fiber in skeletal muscle,55 and to increase skeletal muscle FAO and improve serum lipid profiles and insulin sensitivity in several obesity models in mice.56–58
Recent studies focusing on the role of PPARß in cardiac metabolism have shown that PPARß selective ligands induce expression of mitochondrial FAO enzymes and increase palmitate oxidation rates in neonatal and adult cardiac myocytes as effectively as PPAR-selective ligands.59,60 Furthermore, PPARß activation rescues expression of FAO enzyme genes that are reduced at baseline in PPAR–/– cardiomyocytes.60,61 These results highlight the regulatory overlap between PPAR and PPARß. It is unclear, however, whether PPAR and PPARß regulate discrete, albeit overlapping, sets of genes or superimposed pathways. PPAR and PPARß are not functionally redundant. PPAR–/– mice are phenotypically normal at baseline, but display myocardial lipid accumulation subacutely when subjected to a metabolic stress, and progressively with age, suggesting that PPARß cannot compensate for PPAR under all physiological circumstances.37,40,62
PPAR
PPAR is primarily a regulator of lipid storage and is essential for adipose formation.22,63 Although its expression is adipose tissue-enriched, PPAR is also expressed at low levels in extra-adipose tissues including the vascular wall, skeletal muscle, pancreatic ß-cell, and heart. Thiazolidinediones (TZDs), such as pioglitazone, are PPAR ligands used as insulin sensitizers to treat type II diabetes.64 TZDs are thought to mediate their effects largely through PPAR activation in adipose tissue and skeletal muscle. In adipose tissue, PPAR activation promotes glucose uptake and triglyceride synthesis/storage and inhibits lipolysis, which concurrently increase adipose mass and reduce serum glucose and free FAs. In skeletal muscle, the role of PPAR remains controversial. Murine loss-of-function studies have provided conflicting results regarding the direct role of the muscle PPAR pathway in the development of whole body insulin resistance and in insulin-sensitization by TZDs.65,66
It is generally thought that PPAR modulates cardiac FA utilization through its effects on extra-cardiac tissues. Changes in circulating FAs resulting from PPAR mediated effects on lipid storage will directly modulate PPAR and PPARß activity and affect insulin sensitivity in the heart. Adipose tissue also secretes various signaling factors, such as tumor necrosis factor-, leptin, and adiponectin that affect insulin sensitivity and metabolism in heart and other tissues.67,68 Direct regulation of cardiac metabolism by PPAR is a subject of considerable debate. PPAR is expressed in the heart at levels far below PPAR and ß, and PPAR ligands do not affect metabolic gene expression or FAO rates in cultured cardiac myocytes.59 However, PPAR activation has been shown to inhibit the induction of hypertrophy markers in cardiac myocytes in response hypertrophic stimuli, suggesting that PPAR is functional in these cells. Further studies using cardiac-specific PPAR deletion will be required to determine PPAR regulation of cardiac gene expression is mediated by direct or indirect mechanisms.
|
PGC-1 Family: Inducible NR Coactivators and Integrators of Cardiac Metabolic Gene Regulatory Pathways |
|---|
|
TopAbstractIntroductionNuclear Receptors: A Brief...PPARs: Regulators of Cardiac...PGC-1 Family: Inducible NR...Estrogen-Related Receptors:...Altered NR Signaling in...Future DirectionsReferences |
|---|
PGC-1
was initially identified as a PPAR coactivator, linked to adaptive thermogenesis in brown adipose.69 Two structurally related proteins, PGC-1ß and PRC, have subsequently been cloned and shown to also regulate energy metabolic pathways.70–74 The tissue-specific and inducible nature of PGC-1 expression reflects its role in the dynamic regulation of cellular energy metabolic processes, including mitochondrial biogenesis and oxidation, hepatic gluconeogenesis, and skeletal muscle glucose uptake.75–78 PGC-1 is selectively expressed in highly oxidative tissues such as heart, skeletal muscle, brown adipose, and liver.69 In heart, PGC-1 expression increases sharply at birth coincident with a perinatal shift from glucose metabolism to fat oxidation.79 PGC-1 activity and expression levels are induced by cold exposure, fasting, and exercise; stimuli known to promote oxidative metabolism.79–81 Signaling pathways associated with these stimuli, including p38 MAP kinase, ß-adrenergic/cAMP, nitric oxide, AMP kinase, and Ca2+-calmodulin kinase, activate PGC-1, and its downstream target genes either by increasing PGC-1 expression or transactivation function (Figure 3).82–88
|
PGC-1 mediates its broad metabolic regulatory effects through coactivation of numerous transcription factor partners, including many NRs. Most relevant to the current focus are those linked to cardiac energy metabolism. PGC-1 coactivates PPAR and enhances FA-dependent regulation of PPAR responsive genes involved in the FAO pathway.89 PPARß is also a transcriptional partner for PGC-1.53 Consistent with its functional interaction with PPARs, PGC-1 activates expression of genes involved in FA uptake and oxidation when overexpressed in cardiac myocytes.79 Recent studies, discussed later, have implicated additional orphan NRs in mediating PGC-1 regulation of cardiac energy metabolism.
In addition to activating FA metabolic pathways via PPARs, PGC-1 has been shown to increase mitochondrial oxidative capacity in multiple cell and tissue models.90 PGC-1 overexpression increases mitochondrial number in brown adipocytes and skeletal and cardiac myocytes.69,79,91 In skeletal myocytes, PGC-1 primarily increases uncoupled respiration associated with induction of uncoupling proteins 2 (UCP2) and 3 (UCP3).91 In vivo PGC-1 effects on mitochondrial number and respiration causes a skeletal muscle fiber-type switch from fast glycolytic to slow oxidative.92 In cardiac myocytes, PGC-1 drives mitochondrial biogenesis, increases FAO and overall mitochondrial oxidative capacity in the form of ATP-generating, coupled respiration.79 (J. Huss, unpublished observations, 2004). Global gene expression analyses in cardiac myocytes overexpressing PGC-1 have shown that PGC-1 activates genes encoding enzymes at every level of oxidative energy metabolism, including FA uptake, mitochondrial ß-oxidation, TCA cycle, electron transport, and oxidative phosphorylation79 (L. Russell, unpublished observations, 2004). Finally, in an inducible transgenic model to investigate cardiac-specific effects of PGC-1, PGC-1 overexpression triggered robust mitochondrial biogenesis during the neonatal period. In adult mice, PGC-1 expression led to modest mitochondrial proliferation, mitochondrial ultrastructural abnormalities, and reduced myofibrillar density.93 These metabolic and structural changes resulted in dilated cardiomyopathy and diastolic dysfunction. Interestingly, the mitochondrial proliferation was reversible and the cardiomyopathy rescued on reduction in transgene expression. Collectively, these studies suggest that, in addition to serving as an activator of cellular FA metabolism through PPARs, PGC-1 is linked to the mitochondrial biogenic program. Therefore, PGC-1 serves as a master modulator of oxidative energy metabolism, responsive to changes in the cellular energy status.
The role of PGC-1 in driving mitochondrial biogenesis and oxidative metabolism is consistent with the array of transcription factor partners with which PGC-1 functionally interacts.94 In addition to NRs, PGC-1 coactivates transcription factors involved in regulating mitochondrial biogenesis and oxidative metabolism, including nuclear respiratory factor-1 (NRF-1) and NRF-2. The NRFs directly regulate downstream genes involved in mitochondrial respiratory function and biogenesis, including mitochondrial transcription factor A (Tfam), which is involved in mitochondrial DNA maintenance, replication, and transcription.95,96 NRF-1 and NRF-2 also regulate expression of nuclear genes encoding components of mitochondrial electron transport and oxidative phosphorylation.97 It is likely that additional PGC-1 partners exist in the mitochondrial biogenic cascade.94
|
Estrogen-Related Receptors: Emerging Role for Orphan NRs in Regulating Cardiac Energy Metabolism |
|---|
|
TopAbstractIntroductionNuclear Receptors: A Brief...PPARs: Regulators of Cardiac...PGC-1 Family: Inducible NR...Estrogen-Related Receptors:...Altered NR Signaling in...Future DirectionsReferences |
|---|
Evidence is emerging that the estrogen-related receptor (ERR) family of orphan NRs function as PGC-1-activated regulators of cardiac and skeletal muscle energy metabolism. There are three members of the ERR family: ERR
, ERRß, and ERR.98–100 ERR and ERR expression is enriched in adult tissues that rely primarily on mitochondrial oxidative metabolism for ATP production, such as heart and slow-twitch skeletal muscle.99,101,102 ERR expression dramatically increases in heart after birth, in parallel with the global upregulation of enzymes involved in cellular FA uptake and mitochondrial oxidation.103 Recently, ERR and ERR were identified as novel partners for the PGC-1 family of coactivators.74,103–105 This functional relationship between ERR isoforms and PGC-1 have stimulated interest in the role of ERRs in energy metabolism.
Deletion of the ERR gene reveals a tissue-specific role for ERR in constitutive regulation of lipid metabolism.106 White adipose mass is decreased in ERR–/– mice coincident with decreased adipocyte size and lipid synthesis rates. In contrast, ERR likely plays a role in lipid catabolism in heart, consistent with its functional interaction with PGC-1. ERR–/– mice, which do not display an overt cardiac phenotype, exhibit a compensatory increase in cardiac PGC-1 and ERR expression (J. Huss, unpublished data, 2004). These results suggest that ERR isoforms contribute to constitutive expression of FA metabolic genes in heart. However, the metabolic effects of the observed gene expression changes remain to be explored.
Gene expression profiling in cardiac myocytes overexpressing ERR have begun to identify cardiac ERR target genes. ERR activates genes involved in energy production pathways, including cellular FA uptake (LPL, CD36/FAT, H-FABP, FACS-1), ß-oxidation (MCAD, VLCAD, LCHAD), and mitochondrial electron transport/oxidative phosphorylation (cytochrome c, COXIV, COXVIII, NADH ubiquinone dehydrogenase, flavoprotein-ubiquinone oxidoreductase, ATP synthase ß). ERR also increases palmitate oxidation rates in cardiac myocytes. Activation of ß-oxidation enzymes genes by ERR involves the PPAR signaling pathway. ERR directly activates PPAR gene expression, and ERR-mediated regulation of MCAD and M-CPT I is abolished in cells derived from PPAR–/– mice (J. Huss, unpublished data, 2004). Recently, ERR has also been shown to be involved in the PGC-1 regulation of mitochondrial biogenesis.107,108 ERR was found to mediate PGC-1 activation of the NRF pathway through regulation of the Gapba gene, which encodes a subunit of the NRF-2 complex.108 ERR also directly activates genes involved in mitochondrial oxidative metabolism at the level of transcription. ERR with its coactivator PGC-1 activates the MCAD,101–103 cytochrome c, and ATP synthase ß gene promoters.107 Collectively, these results identify ERR as a regulator of cardiac oxidative energy metabolism through its involvement in the PGC-1 regulatory circuit. Studies using animal models of cardiac-specific ERR and ERR activation or inactivation will be essential to delineate the precise biologic roles of ERRs in heart.
|
Altered NR Signaling in the Diseased Heart: Driver or Passenger? |
|---|
|
TopAbstractIntroductionNuclear Receptors: A Brief...PPARs: Regulators of Cardiac...PGC-1 Family: Inducible NR...Estrogen-Related Receptors:...Altered NR Signaling in...Future DirectionsReferences |
|---|
A central question regarding cardiac metabolism is the role that perturbations in cardiac energy transfer pathways play in the development of pathological cardiac remodeling and heart failure. Inherited and acquired forms of heart failure are associated with an overall decrease in mitochondrial oxidative capacity and a shift away from FA oxidation toward glucose utilization (Figure 4).19,109,110 It is unclear whether this metabolic shift is a protective response allowing the heart to maintain contractile function or an initial step in progressive decompensation. Conversely, diabetic cardiomyopathy develops in the context of chronically high FAO and inhibited glucose uptake and oxidation. Although this switch in fuel utilization may initially be adaptive, the drive on FA utilization and loss of substrate utilization flexibility may become an etiological component of the disease.111,112
|
Altered PPAR Signaling in Pressure Overload Induced-Hypertrophy and Heart Failure
During the progression of pathological cardiac hypertrophy in animal models and humans, the heart undergoes a shift from FAO toward increased glucose utilization (Figure 4).13,113 This metabolic switch is driven by the coordinated counter-regulation of FAO and glucose-metabolizing enzyme genes14,19 Evidence implicates deactivation of the PPAR signaling pathway as the mechanism driving downregulation of FAO genes in the hypertrophied heart. Reduced expression and activity of PPAR closely correlates with decreased ß-oxidation observed in cardiac hypertrophy.114–116 PPAR-dependent activity of the M-CPT I gene promoter is inhibited by the 1-agonist, phenylephrine, which induces hypertrophic growth and decreases FAO rates in cardiac myocytes.114 Inhibition of the PPAR signaling pathway involves both early and late events. PPAR is rapidly deactivated by extracellular signal-regulated MAP kinase phosphorylation.114 At later stages of hypertrophic growth, transcriptional repressors of FAO genes, such as the orphan NR COUP-TF, are induced and inhibit PPAR activation of FAO target genes.115
Although PPAR activity and cardiac substrate utilization influence the response to hypertrophic stimuli, decreased PPAR activity and FA metabolism are not thought to drive progression of pathological hypertrophy to heart failure. In fact, the metabolic switch in early stages of pathological hypertrophy may be protective. PPAR activation in rats subjected to pressure-overload induced hypertrophy prevents the metabolic switch and results in mild contractile dysfunction.117 PPAR activity also influences hypertrophic growth. The PPAR ligands, fenofibrate and Wy14,463, inhibited cardiac myocyte hypertrophy in response to endothelin.118 Human genetic studies identified a significant association between a PPAR gene polymorphism and development of physiological or pathological left ventricular hypertrophy though did not establish that the anti-hypertrophic effects of PPAR were linked to metabolic changes.119 Similar antihypertrophic action has been observed for other NR ligands, including 1,25 dihydroxyvitamin D and retinoic acid, which act through vitamin D receptor (VDR)/RXR heterodimers.120 Finally, recent studies demonstrated that the PPAR ligands, TZDs, inhibited hypertrophic growth in cardiac myocytes in response to mechanical stress and angiotensin II treatment.121,122 Pioglitazone treatment in mice inhibited pressure-overload induced increases in heart weight, wall thickness, and myocyte size.122
Diabetic Cardiomyopathy
Epidemiological studies have demonstrated that the incidence of cardiomyopathy in diabetics is significantly increased independent of additional risk factors, such as hypertension and vascular disease, present in diabetics.123 Therefore, attention has focused on the role diabetes-related metabolic dysregulation plays in the development of cardiomyopathy.112,124 In the diabetic state, cardiac energy demands are almost entirely fueled by FAO, a consequence of impaired glucose uptake and metabolism attributable to myocardial insulin resistance and increased circulating FAs.17,18 Leptin-deficient obese (ob/ob) mice and Zucker fatty rats exhibit myocardial triglyceride accumulation and increased expression of genes involved in lipid uptake and triglyceride synthesis.125,126 In both models, ventricular mass was increased. Functionally, decreased contractile function observed in Zucker fatty rats was attributed to lipotoxic effects of the accumulated lipid species.127 These studies implicate defective PPAR signaling in these models, causing a mismatch between FA uptake and metabolism.127 Indeed, the cardiac PPAR signaling pathway is activated in diabetic rodent models, including streptozotocin (STZ)-induced diabetes and the obese db/db mice, as evidenced by increased expression of PGC-1, PPAR, and downstream metabolic target genes.20 Furthermore, PPAR–/– mice are resistant to cardiomyopathy that develops in STZ-induced diabetic wild-type mice.128 The observed induction of cardiac PGC-1 expression in diabetic mice contrasts with the downregulation of PGC-1 and mitochondrial oxidative phosphorylation enzymes reported in insulin resistant skeletal muscle.129,130
The MHC-PPAR model has demonstrated a direct relationship between the chronic drive on myocardial FA metabolism and the development of cardiomyopathy.20 Cardiac PPAR overexpression replicates the diabetic metabolic profile: myocardial triglyceride accumulation, increased FAO rates, and decreased glucose uptake and metabolism. MHC-PPAR mice develop ventricular hypertrophy and dysfunction that is exacerbated with high fat feeding.128 These studies demonstrate the relationship between cardiac metabolic derangement and dysfunction and suggest that PPAR-driven increases in FA uptake and oxidation contribute to diabetic cardiomyopathy. Cardiac dysfunction in MHC-PPAR mice may be caused by toxic effects of myocardial lipid accumulation or free radical damage from chronically high oxidative flux. This model has important implications for human disease because it mimics the cardiac metabolic derangement that is chronic in obesity-related disorders, particularly type II diabetes.
Implications from studies of the MHC-PPAR mice are that activation of PPAR and downstream FA metabolism may contribute to heart failure progression in the diabetic. Thus, PPAR inhibition may be a means to delay or prevent heart failure in diabetic patients. Inhibiting mitochondrial ß-oxidation with 3-ketoacyl-CoA thiolase inhibitors, such as trimetazidine, increased cardiac efficiency in patients with diabetes and ischemic cardiomyopathy by shifting metabolism toward glucose oxidation.131,132 However, chronic FAO inhibition may also predispose the heart to lipid accumulation and subsequent lipotoxicity. Furthermore, PPAR agonists are used to treat hyperlipidemia, a major risk factor for atherosclerosis. Bezafibrate and gemfibrozil improve serum lipid profiles in type II diabetics, reducing serum triglycerides and increasing HDL levels.133,134 The VA-HIT study, which investigated the link between diabetes and cardiovascular outcomes, showed that gemfibrozil treatment reversed the increased incidence of major cardiovascular events associated with diabetes and low HDL cholesterol.135 The weight of clinical data suggests that systemic activation of the PPAR pathway in diabetics improves cardiovascular outcome likely via extracardiac effects. Clearly, additional studies are necessary to predict the effects of modulating lipid metabolism in the prevention and treatment of cardiomyopathy in the diabetic.
|
Future Directions |
|---|
|
TopAbstractIntroductionNuclear Receptors: A Brief...PPARs: Regulators of Cardiac...PGC-1 Family: Inducible NR...Estrogen-Related Receptors:...Altered NR Signaling in...Future DirectionsReferences |
|---|
This review sought to provide a view of the current state of knowledge regarding the regulation of cardiac metabolism by NRs. As ligand-responsive transcription factors, NRs are well suited to respond to fluctuations in substrates and metabolic intermediates and to regulate pathways involved in their catabolism. Given the explosion of new information about PPARs and the development of isoform-specific PPAR agonists, this group comprises an important potential therapeutic target to modulate cardiac energy metabolism. Several challenges must be addressed to use NR modulators as therapeutic agents for myocardial disease. We must first determine whether NR-driven alterations in cardiac metabolism are adaptive or maladaptive in the hypertrophied or diabetic state. Another important consideration is the lack of tissue specificity of the compounds. Future studies combining tissue-selective genetic mouse models and pathophysiological models of hypertrophy and diabetes will test the utility of existing and novel NR ligands as potential therapies for heart failure.
|
Acknowledgments |
|---|
This work was supported by NIH grants R01 DK45416.R01 HL58493, PO1 HL57278, and the Digestive Diseases Core Center Grant P30 DK52574 (D.P.K). J.M.H. is supported by NIH grant K01 DK063051 and the Washington University School of Medicine Diabetes Research Training Center P60 DK20579 (J.M.H.). We thank Laurie K. Russell for allowing discussion of unpublished data. We also thank Mary Wingate for expert assistance in manuscript preparation.
|
Footnotes |
|---|
Original received April 16, 2004; revision received July 2, 2004; accepted July 2, 2004.
|
References |
|---|
|
TopAbstractIntroductionNuclear Receptors: A Brief...PPARs: Regulators of Cardiac...PGC-1 Family: Inducible NR...Estrogen-Related Receptors:...Altered NR Signaling in...Future DirectionsReferences |
|---|
1. Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev. 2002; 7: 115–130.[CrossRef][Medline] [Order article via Infotrieve]
2. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr Prob Cardiol. 1994; 19: 59–113.[Medline] [Order article via Infotrieve]
3. Bing RJ, Siegel A, Ungar I, Gilbert M. Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. Am J Med. 1954; 16: 504–515.[CrossRef][Medline] [Order article via Infotrieve]
4. Shipp JC, Opie LH, Challoner D. Fatty acid and glucose metabolism in the perfused heart. Nature. 1961; 189: 1018–1019.[CrossRef]
5. Wisnecki JA, Gertz EQ, Neese RA, Mayr M. Myocardial metabolism of free fatty acids: Studies with14C labelled substrates in humans. J Clin Invest. 1987; 79: 359–366.[Medline] [Order article via Infotrieve]
6. Schaffer JE, Lodish HF. Expression cloning and characterization of a novel adipocyte long-chain fatty acid transport protein. Cell. 1994; 79: 427–436.[CrossRef][Medline] [Order article via Infotrieve]
7. Abumrad NA, el-Maghrabi MR, Amri EZ, Lopez E, Grimaldi PA. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiaion. Homology with human CD36. J Biol Chem. 1993; 268: 17665–17668.
8. Breuer E, Barta E, Zlatos L, Pappova E. Developmental changes in myocardial metabolism. II. Myocardial metabolism of fatty acids in the early postnatal period in dogs. Biol Neonate. 1968; 12: 54–64.
9. Warshaw JB. Cellular energy metabolism during fetal development. IV. Fatty acid activation, acyl transfer and fatty acid oxidation during development of the chick and rat. Dev Biol. 1972; 28: 537–544.[CrossRef][Medline] [Order article via Infotrieve]
10. Kelly DP, Whelan AJ, Ogden ML, Alpers R, Zhang ZF, Bellus G, Gregersen N, Dorland L, Strauss AW. Molecular characterization of inherited medium-chain acyl-CoA dehydrogenase deficiency. Proc Natl Acad Sci U S A. 1990; 87: 9236–9240.
11. Aoyama T, Uchida Y, Kelley RI, Marble M, Hofman K, Tonsgard JH, Rhead WJ, Hashimoto T. A novel disease with deficiency of mitochondrial very-long-chain acyl-CoA dehydrogenase. Biochem Biophys Res Commun. 1993; 191: 1369–1372.[CrossRef][Medline] [Order article via Infotrieve]
12. Kelly DP, Strauss AW. Inherited cardiomyopathies. N Engl J Med. 1994; 330: 913–919.
13. Taegtmeyer H, Overturf ML. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension. 1988; 11: 416–426.
14. Depre C, Shipley GL, Chen W, Han Q, Doenst T, Moore ML, Stepkowski S, Davies PJA, Taegtmeyer H. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med. 1998; 4: 1269–1275.[CrossRef][Medline] [Order article via Infotrieve]
15. El-Alaoui-Talibi Z, Landormy A, Loireau A, Morovec J. Fatty acid oxidation and mechanical performance of volume overloaded rat hearts. Am J Physiol. 1992; 262: H1068–H1074.[Medline] [Order article via Infotrieve]
16. Allard MF, Schonekess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol. 1994; 267: H742–H750.[Medline] [Order article via Infotrieve]
17. Wall SR, Lopaschuk GD. Glucose oxidation rates in fatty acid perfused isolated working hearts from diabetic rat. Biochim Biophys Acta. 1989; 1006: 97–103.[Medline] [Order article via Infotrieve]
18. Saddik M, Lopaschuk GD. Triacylglycerol turnover in isolated working hearts of acutely diabetic rats. Can J Physiol Pharmocol. 1994; 72: 1110–1119.[Medline] [Order article via Infotrieve]
19. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation. 1996; 94: 2837–2842.
20. Finck B, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPAR overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002; 109: 121–130.[CrossRef][Medline]
[Order article via Infotrieve]
21. Maglich JM, Sluder A, Guan X, Shi Y, McKee DD, Carrick K, Kamdar K, Willson TM, Moore JT. Comparison of complete nuclear receptor sets from the human, Caenorhabditis elegans and Drosophila genomes Genome Biology. 2001; 2: 1–7.
22. Lee C-H, Olson P, Evans RM. Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology. 2003; 144: 2201–2207.
23. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: Opening the X-files. Science. 2001; 294: 1866–1870.
24. Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Annu Rev Physiol. 2003; 65: 261–311.[CrossRef][Medline] [Order article via Infotrieve]
25. McKenna NJ, Lanz RB, O’Malley BW. Nuclear receptor coregulators: Cellular and molecular biology. Endocrine Reviews. 1999; 20: 321–344.
26. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocrine Reviews. 1999; 20: 649–688.
27. Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res. 2001; 56: 239–263.[Abstract]
28. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996; 137: 354–366.[Abstract]
29. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology. 2001; 142: 4195–4202.
30. Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trend Cardiovasc Med. 2000; 10: 238–245.[CrossRef][Medline] [Order article via Infotrieve]
31. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors and . Proc Natl Acad Sci U S A. 1997; 94: 4312–4317.
32. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPAR-leukotriene B4 pathway to inflammation control. Nature. 1996; 384: 39–43.[CrossRef][Medline]
[Order article via Infotrieve]
33. Gulick T, Cresci S, Caira T, Moore DD, Kelly DP. The peroxisome proliferator activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U S A. 1994; 91: 11012–11016.
34. Disch DL, Rader TA, Cresci S, Leone TC, Barger PM, Vega R, Wood PA, Kelly DP. Transcriptional control of a nuclear gene encoding a mitochondrial fatty acid oxidation enzyme in transgenic mice: role for nuclear receptors in cardiac and brown adipose expression. Mol Cell Biol. 1996; 16: 4043–4051.[Abstract]
35. Lee SST, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ. Targeted disruption of the isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 1995; 15: 3012–3022.[Abstract]
36. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor (PPAR). J Biol Chem. 1998; 273: 5678–5684.
37. Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y, Ono T, Hasegawa G, Naito M, Nakajima T, Kamijo Y, Gonzalez FJ, Aoyama T. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor associated with age-dependent cardiac toxicity. J Biol Chem. 2000; 275: 22293–22299.
38. Djouadi F, Brandt J, Weinheimer CJ, Leone TC, Gonzalez FJ, Kelly DP. The role of the peroxisome proliferator-activated receptor (PPAR) in the control of cardiac lipid metabolism. Prostaglandins Leukot Essent Fatty Acids. 1999; 60: 339–343.[CrossRef][Medline]
[Order article via Infotrieve]
39. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JRB, Belke DD, Severson DL, Kelly DP, Lopaschuk GD. A role for PPAR in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPAR are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem. 2002; 277: 4098–4103.
40. Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPAR) in the cellular fasting response: The PPAR-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci U S A. 1999; 96: 7473–7478.
41. Nagao M, Parimoo B, Tanaka K. Developmental, nutritional, and hormonal regulation of tissue-specific expression of the genes encoding various acyl-CoA dehydrogenases and -subunit of electron transfer flavoprotein in rat. J Biol Chem. 1993; 268: 24114–24124.
42. Hopkins TA, Sugden MC, Holness MJ, Kozak R, Dyck JRB, Lopaschuk GD. Control of cardiac pyruvate dehydrogenase activity in peroxisome proliferator-activated receptor- transgenic mice. Am J Physiol Heart Circ Physiol. 2003; 285: H270–H276.
43. Randle PJ, Hales CN, Garland PB. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabeties mellitus. Lancet. 1963; 1: 785–789.[Medline] [Order article via Infotrieve]
44. Randle PJ. Regulation of glycolysis and pyruvate oxidation in cardiac muscle. Circ Res. 1976; 38: 8–12.
45. Michalik L, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors ß/: emerging roles for a previously neglected third member. Curr Opin Lipidol. 2003; 14: 129–135.[CrossRef][Medline]
[Order article via Infotrieve]
46. Chawla A, Lee C-H, Barak Y, He W, Rosenfeld J, Liao D, Han J, Kang H, Evans RM. PPAR is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci U S A. 2003; 100: 1268–1273.
47. Hihi AK, Michalik L, Wahli W. PPARs: transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci. 2002; 98: 13919–13924.
48. Peters JM, Lee SST, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, Gonzalez FJ. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor ß(). Mol Cell Biol. 2000; 20: 5119–5128.
49. Barak Y, Liao D, He W, Ong ES, Melson MC, Olefsky JM, Boland R, Evans RM. Effects of peroxisome proliferator-activated delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A. 2002; 99: 303–308.
50. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, Peters JM, Kaya G, Gonzalez FJ, Zakany J, Metzger D, Chambon P, Duboule D, Wahli W. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol. 2001; 154: 799–814.
51. Muoio DM, MacLean PS, Lang DB, Li S, Houmard JA, Way JM, Winegar DA, Gorton JC, Dohm GL, Kraus WE. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta. J Biol Chem. 2002; 277: 26089–26097.
52. Holst D, Luquet S, Nogueira V, Kristiansen K, Leverve X, Grimaldi PA. Nutritional regulation and role of peroxisome proliferator-activated receptor delta in fatty acid catabolism in skeletal muscle. Biochim Biophys Acta. 2003; 1633: 43–50.[Medline] [Order article via Infotrieve]
53. Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GE. The peroxisome proliferator-activated receptor ß/ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol. 2003; 17: 2477–2493.
54. Wang Y-X, Lee C-H, Tiep S, Yu RT, Ham J, Kang H, Evans RM. Peroxisome-proliferator-activated receptor activates fat metabolism to prevent obesity. Cell. 2003; 113: 159–170.[CrossRef][Medline]
[Order article via Infotrieve]
55. Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, Rassoulzadegan M, Grimaldi P. Peroxisome proliferator-activated receptor controls muscle development and oxidative capability. FASEB J. 2003; 17: 2299–2301.
56. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisawa M, Kodama T, Sakai J. Activation of peroxisome proliferator-activated receptor induces fatty acid ß-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A. 2003; 100: 15924–15929.
57. Oliver Jr WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective peroxisome proliferator-activated receptor agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A. 2001; 98: 5306–5311.
58. Leibowitz MD, Fievet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Bergera H, Cullinan CA, Sparrow CP, Baffic J, Berger GD, Santini C, Marquis RW, Tolman RL, Smith RG, Moller DE, Auwerx J. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett. 2000; 473: 333–336.[CrossRef][Medline] [Order article via Infotrieve]
59. Gilde AJ, van der Lee KAJM, Willemsen PHM, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, van Bilsen M. PPAR and PPARß/, but not PPAR, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res. 2003; 92: 518–524.
60. Cheng L, Ding G, Qin Q, Xiao Y, Woods D, Chen YE, Yang Q. Peroxisome proliferator-activated receptor activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes. Biochem Biophys Res Commun. 2004; 313: 277–286.[CrossRef][Medline]
[Order article via Infotrieve]
61. DeLuca JG, Doebber TW, Kelly LJ, Kemp RK, Molon-Noblot S, Sahoo SP, Vemtre J, Wu MS, Peters JM, Gonzalez FJ, Moller DE. Evidence for peroxisome proliferator-activated receptor (PPAR) -independent peroxisome proliferation: effects of PPAR/ß-specific agonists in PPAR-null mice. Mol Pharmacol. 2000; 58: 470–476.
62. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor mediates the adaptive response to fasting. J Clin Invest. 1999; 103: 1489–1498.[Medline]
[Order article via Infotrieve]
63. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM. PPAR is required for placental,cardiac,and adipose tissue development. Mol Cell. 1999; 4: 585–595.[CrossRef][Medline]
[Order article via Infotrieve]
64. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferannini E, Cusi K, Mandarino LJ, DeFronzo RA. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001; 24: 710–719.
65. Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, Olefsky J. Muscle-specific Pparg deletion causes insulin resistance. Nat Med. 2003; 9: 1491–1497.[CrossRef][Medline] [Order article via Infotrieve]
66. Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, Kahn CR. Muscle-specific PPAR-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest. 2004; 112: 608–618.
67. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002; 8: 731–737.[CrossRef][Medline] [Order article via Infotrieve]
68. Atkinson LL, Fischer MA, Lopaschuk GD. Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis. J Biol Chem. 2002; 277: 29424–29430.
69. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 1998; 92: 829–839.[CrossRef][Medline] [Order article via Infotrieve]
70. Andersson U, Scarpulla RC. PGC-1-Related coactivator, a novel, serum-inducible coactivator of nuclear respiratory factor-1-dependent transcription in mammalian cells. Mol Cell Biol. 2001; 21: 3738–3749.
71. Lin J, Puigserver P, Donovan J, Tarr P, Spiegelman BM. Peroxisome proliferator-activated receptor coactivator 1ß (PGC-1ß), a novel PGC-1-related transcription coactivator associated with host cell factor. J Biol Chem. 2002; 277: 1645–1648.
72. Lin J, Tarr PT, Yang R, Rhee J, Puigserver P, Newgard CB, Spiegelman BM. PGC-1beta in the regulation of hepatic glucose and energy metabolism. J Biol Chem. 2003; 278: 30843–30848.
73. Kressler D, Schreiber SN, Knutti D, Kralli A. The PGC-1-related protein PERC is a selective coactivator of estrogen receptor alpha. J Biol Chem. 2002; 277: 13918–13925.
74. Kamei Y, Ohizumi H, Fujitani Y, Nemoto T, Tanaka T, Takahashi N, Kawada T, Miyoshi M, Ezaki O, Kakizuka A. PPAR coactivator 1ß/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity. Proc Natl Acad Sci U S A. 2003; 100: 12378–12383.
75. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK, Newgard CB, Spiegelman BM. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 2001; 413: 131–138.[CrossRef][Medline] [Order article via Infotrieve]
76. Michael LF, Wu Z, Cheatham RB, Puigserver P, Adelmant G, Lehman JJ, Kelly DP, Spiegelman BM. Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad Sci U S A. 2001; 98: 3820–3825.
77. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, Rudolph D, Schutz G, Yoon C, Puigserver P, Spiegelman B, Montminy M. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 2001; 413: 179–183.[CrossRef][Medline] [Order article via Infotrieve]
78. Rhee J, Inoue Y, Yoon JC, Puigserver P, Fam M, Gonzalez FJ, Spiegelman BM. Regulation of hepatic fasting response by PPAR coactivator-1 (PGC-1): requirement for hepatocyte nuclear factor 4 in gluconeogenesis. Proc Natl Acad Sci U S A. 2003; 100: 4012–4017.
79. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros D, Kelly DP. PPAR coactivator-1 (PGC-1) promotes cardiac mitochondrial biogenesis. J Clin Invest. 2000; 106: 847–856.[Medline]
[Order article via Infotrieve]
80. Goto M, Terada S, Kato M, Katoh M, Yokozeki T, Tabata I, Shimokawa T. cDNA cloning and mRNA analysis of PGC-1 in epitrochlearis muscle in swimming-exercised rats. Biochem Biophys Res Commun. 2000; 274: 350–354.[CrossRef][Medline] [Order article via Infotrieve]
81. Baar K, Wende AR, Jones TE, Marison M, Nolte LA, Chen M, Kelly DP, Holloszy JO. Adaptations of skeletal muscle to exercise: Rapid increase in the transcriptional coactivator PGC-1. FASEB J. 2002; 16: 1879–1886.
82. Puigserver P, Rhee J, Lin J, Wu Z, Yoon JC, Zhang C-Y, Kraquss S, Mootha VK, Lowell BB, Spiegelman BM. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPAR coactivator-1. Mol Cell. 2001; 8: 971–982.[CrossRef][Medline]
[Order article via Infotrieve]
83. Wu H, Kanatous SB, Thurmond FA, Gallardo T, Isotani E, Bassel-Duby R, Williams RS. Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science. 2002; 296: 349–352.
84. Handschin C, Rhee J, Lin J, Tam PT, Spiegelman BM. An autoregulatory loop controls peroxisome proliferator-activated receptor coactivator 1 expression in muscle. Proc Natl Acad Sci U S A. 2003; 100: 7111–7116.
85. Boss O, Bachman E, Vidal-Puig A, Zhang C-Y, Peroni O, Lowell BB. Role of the ß3-Adrenergic receptor and/or putative ß4-Adrenergic receptor on the expression of uncoupling proteins and peroxisome proliferator-activated receptor- coactivator-1. Biochem Biophys Res Commun. 1999; 261: 870–876.[CrossRef][Medline]
[Order article via Infotrieve]
86. Knutti D, Kressler D, Kralli A. Regulation of the transcriptional coactivator PGC-1 via MAPK-sensitive interaction with a corepressor. Proc Natl Acad Sci U S A. 2001; 98: 9713–9718.
87. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, Bracale R, Valerio A, Francolini M, Moncada S, Carruba MO. Mitochondrial biogenesis in mammals: The role of endogenous nitric oxide. Science. 2003; 299: 896–899.
88. Fan M, Rhee J, St-Pierre J, Handschin C, Puigserver P, Lin J, Jaeger S, Erdjument-Bromage H, Tempst P, Spiegelman BM. Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK. Genes Dev. 2004; 18: 278–289.
89. Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol. 2000; 20: 1868–1876.
90. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor- coactivator 1 (PGC-1): Transcriptional coactivator and metabolic regulator. Endocrine Reviews. 2003; 24: 78–90.
91. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 1999; 98: 115–124.[CrossRef][Medline] [Order article via Infotrieve]
92. Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, Michael LF, Puigserver P, Isotanni E, Olson EN, Lowell BB, Bassel-Duby R, Spiegelman BM. Transcriptional co-activator PGC-1 drives the formation of slow-twitch muscle fibres. Nature. 2002; 418: 797–801.[CrossRef][Medline]
[Order article via Infotrieve]
93. Russell LK, Mansfield CM, Lehman JJ, Kovacs A, Courtois M, Saffitz JE, Medeiros DM, Valencik ML, McDonald JA, Kelly DP. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-actived receptor coactivator-1 promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res. 2004; 94: 525–533.
94. Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 2004; 18: 357–368.
95. Larsson N-G, Wang JM, Wilhelmsson H, Oldfors A, Rustin P, Lewandoski M, Barsh GS, Clayton DA. Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat Genet. 1998; 18: 231–236.[CrossRef][Medline] [Order article via Infotrieve]
96. Garesse R, Vallejo CG. Animal mitochondrial biogenesis and function: a regulatory cross-talk between two genomes. Gene. 2001; 263: 1–16.[CrossRef][Medline] [Order article via Infotrieve]
97. Scarpulla RC. Nuclear activators and coactivators in mammalian mitochondrial biogenesis. Biochim Biophys Acta. 2002; 1576: 1–14.[Medline] [Order article via Infotrieve]
98. Giguère V, Yang N, Segui P, Evans RM. Identification of a new class of steroid hormone receptors. Nature. 1988; 331: 91–94.[CrossRef][Medline] [Order article via Infotrieve]
99. Heard DJ, Norbu PL, Holloway J, Vissing H. Human ERR, a third member of the estrogen receptor-related receptor (ERR) subfamily of orphan nuclear receptors: Tissue-specific isoforms are expressed during development and in the adult. Mol Endocrinol. 2000; 14: 383–392.
100. Hong H, Yang L, Stallcup MR. Hormone-independent transcriptional activation and coactivator binding by novel orphan nuclear receptor ERR3. J Biol Chem. 1999; 274: 22618–22626.
101. Sladek R, Bader J-A, Giguère V. The orphan nuclear receptor estrogen-related receptor is a transcriptional regulator of the human medium-chain acyl coenzyme a dehydrogenase gene. Mol Cell Biol. 1997; 17: 5400–5409.[Abstract]
102. Vega RB, Kelly DP. A role for estrogen-related receptor alpha in the control of mitochondrial fatty acid beta-oxidation during brown adipocyte differentiation. J Biol Chem. 1997; 272: 31693–31699.
103. Huss JM, Kopp RP, Kelly DP. PGC-1 coactivates the cardiac-enriched nuclear receptors estrogen-related receptor- and -. J Biol Chem. 2002; 277: 40265–40274.
104. Schreiber SN, Knutti D, Brogli K, Uhlmann T, Kralli A. The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor (ERR). J Biol Chem. 2003; 278: 9013–9018.
105. Hentschke M, Susens U, Borgmeyer U. PGC-1 and PERC, coactivators of the estrogen receptor-related receptor gamma. Biochem Biophys Res Commun. 2002; 299: 872–879.[CrossRef][Medline] [Order article via Infotrieve]
106. Luo J, Sladek R, Carrier J, Bader JA, Richard D, Giguere V. Reduced fat mass in mice lacking orphan nuclear receptor estrogen-related receptor alpha. Mol Cell Biol. 2003; 23: 7947–7956.
107. Schreiber SN, Emter R, Hock MB, Knutti D, Cardenas J, Podvinec M, Oakeley EJ, Kralli A. The estrogen-related receptor alpha (ERR) functions in PPAR coactivator 1 (PGC-1) - induced mitochonrial biogenesis. Proc Natl Acad Sci U S A. 2004; 101: 6472–6477.
108. Mootha VK, Handschin C, Arlow D, Xie X, St.Pierre J, Sihag S, Yang W, Altshuler D, Puigserver P, Patterson N, Willy PJ, Schulman IG, Heyman RA, Lander ES, Spiegelman BM. ERR and Gabpa/b specify PGC-1-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc Natl Acad Sci U S A. 2004; 101: 6570–6575.
109. Recchia FA, McConnell PI, Bernstein RD, Vogel TR, Xu X, Hintze TH. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res. 1998; 83: 969–979.
110. Lesnefsky EJ, Tandler B, Ye J, Slabe TJ, Turkaly J, Hoppel CL. Myocardial ischemia decreases oxidative phosphorylation through cytochrome oxidase in subsarcolemmal mitochondria. Am J Physiol. 1997; 273: H1544–H1554.[Medline] [Order article via Infotrieve]
111. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci. 2001; 321: 225–236.[CrossRef][Medline] [Order article via Infotrieve]
112. Lopaschuk GD. Abnormal mechanical function in diabetes: relationship to altered myocardial carbohydrate/lipid metabolism. Coron Artery Dis. 1996; 7: 116–123.[Medline] [Order article via Infotrieve]
113. Bishop SP, Altschuld RA. Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. Am J Physiol. 1970; 218: 153–159.
114. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of peroxisome proliferator-activated receptor- during cardiac hypertrophic growth. J Clin Invest. 2000; 105: 1723–1730.[Medline]
[Order article via Infotrieve]
115. Sack MN, Disch DL, Rockman HA, Kelly DP. A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program. Proc Natl Acad Sci U S A. 1997; 94: 6438–6443.
116. Kanda H, Nohara R, Hasegawa K, Kishimoto C, Sasayama S. A nuclear complex containing PPAR/RXR is markedly downregulated in the hypertrophied rat left ventricular myocardium with normal systolic function. Heart Vessels. 2000; 15: 191–196.[CrossRef][Medline]
[Order article via Infotrieve]
117. Young ME, Laws FA, Goodwin GW, Taegtmeyer H. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem. 2001; 276: 44390–44395.
118. Liang F, Wang F, Zhang S, Gardner DG. Peroxisome proliferators activated receptor (PPAR) agonists inhibit hypertrophy of neonatal rat cardiac myocytes. Endocrinology. 2003; 144: 4187–4194.
119. Jamshidi Y, Montgomery HE, Hense H-W, Myerson SG, Torra IP, Staels B, World MJ, Doering A, Erdmann J, Hengstenberg C, Humphries SE, Schunkert H, Flavell DM. The PPAR gene regulates left ventricular growth in response to exercise and hypertension. Circulation. 2002; 105: 950–955.
120. Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 vitamin D3 and retinoic acid antagonize endothelin stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest. 1996; 97: 1577–1588.[Medline] [Order article via Infotrieve]
121. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K. Peroxisome proliferator-activated receptor activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation. 2001; 104: 1670–1675.
122. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T, Komuro I. Peroxisome proliferator-activated receptor plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 2002; 105: 1240–1246.
123. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with glomerulosclerosis. Am J Cardiol. 1972; 30: 595–602.[CrossRef][Medline] [Order article via Infotrieve]
124. Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol. 2000; 279: E1104–E1113.
125. Christoffersen C, Bollano E, Lindegaard MLS, Bartels ED, Goetze JP, Andersen CB, Nielsen LB. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology. 2003; 144: 3483–3490.[CrossRef][Medline] [Order article via Infotrieve]
126. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human disease. Proc Natl Acad Sci U S A. 2000; 97: 1784–1789.
127. Young ME, Guthrie PH, Razeghi P, Leighton B, Abbasi S, Patil S, Youker KA, Taegtmeyer H. Impaired long-chain fatty acid oxidation and contractile dysfunction in obese zucker rat heart. Diabetes. 2002; 51: 2587–2595.
128. Finck B, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP. A critical for PPAR-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation of phenotype by dietary fat content. Proc Natl Acad Sci U S A. 2003; 100: 1226–1231.
129. Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman BM, Lander ES, Hirschhorn JN, Altshuler D, Groop LC. PGC-1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003; 34: 267–273.[CrossRef][Medline]
[Order article via Infotrieve]
130. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, Landaker EJ, Goldfine AB, Mun E, DeFronzo R, Finlayson J, Kahn CR, Mandarino LJ. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A. 2003; 100: 8466–8471.
131. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme a thiolase. Circ Res. 2000; 86: 580–588.
132. Fragasso G, Piatti PM, Monti L, Palloshi A, Setola E, Puccetti P, Calori G, Lopaschuk GD, Margonato A. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003; 146: e18.[CrossRef][Medline] [Order article via Infotrieve]
133. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992; 15: 820–825.[Abstract]
134. Wagner AM, Jorba O, Bonet R, Ordonez-Llanos J, Perez A. Efficacy of atorvastatic and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab. 2003; 88: 3212–3217.
135. Bloomfield Rubins H, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW. Diabetes, Plasma Insulin, and Cardiovascular Disease: Subgroup Analysis From the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med. 2002; 162: 2597–2604.
136. Schoonjans K, Peinado-Onsurbe AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J. PPAR and PPAR activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996; 15: 5336–5348.[Medline]
[Order article via Infotrieve]
137. van der Lee KAJM, Vork MM, de Vries JE, Willemsen PHM, Glatz JFC, Reneman RS, Van der Vusse GJ, Van Bilsen M. Long-chain fatty acid-induced changes in gene expression in neonatal cardiac myocytes. J Lipid Res. 2000; 41: 41–47.
138. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPAR and PPAR activators. J Biol Chem. 1997; 272: 28210–28217.
139. Frohnert BI, Hui TY, Bernlohr DA. Identification of a functional peroxisome proliferator-activated responsive element in the murine fatty acid transport protein gene. J Biol Chem. 1999; 274: 3970–3977.
140. Schoonjans K, Watanabe M, Suzuki H, Mahfoudi A, Krey G, Wahli W, Grimaldi P, Staels B, Yamamoto T, Auwerx J. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem. 1995; 270: 19269–19276.
141. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N. Expression of Putative Fatty Acid Transporter Genes Are Regulated by Peroxisome Proliferator-activated Receptor and Activators in a Tissue- and Inducer-specific Manner. J Biol Chem. 1998; 273: 16710–16714.
142. Brandt JM, Djouadi F, Kelly DP. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor . J Biol Chem. 1998; 273: 23786–23792.
143. Mascaro C, Acosta E, Ortiz JA, Marrero PF, Hegardt FG, Haro D. Control of human muscle-type carnitine palmitoyltransferase Iß gene promoters by fatty acid enzyme substrate. J Biol Chem. 1998; 273: 32901–32909.
144. Osumi T, Wen JK, Hashimoto T. Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of the rat acyl-CoA oxidase gene. Biochem Biophys Res Commun. 1991; 175: 866–871.[CrossRef][Medline] [Order article via Infotrieve]
145. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G Wahli W. Control of the peroxisomal ß-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 1992; 68: 879–887.[CrossRef][Medline] [Order article via Infotrieve]
146. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S. The mouse peroxisome proliferator-activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 1992; 11: 433–439.[Medline] [Order article via Infotrieve]
147. Varanassi U, Chu R, Huant Q, Castellon R, Yeldandi AV, Reddy JK. Identification of a peroxisome proliferators-response element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J Biol Chem. 1996; 271: 2147–2155.
148. Zhang BW, Marcus SL, Sajjadi FG, Alvares K, Reddy JK, Subramani S, Rachubinski RA, Capone JP. Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase. Proc Natl Acad Sci. 1992; 85: 7541–7545.
149. Bardot O, Aldridge TC, Latruffe N, Green S. PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochem Biophys Res Commun. 1993; 19: 237–245.
150. Sugden MC, Bulmer K, Gibbons GF, Holness MJ. Role of Peroxisome Proliferator-Activated Receptor- in the mechanism underlying changes in renal pyruvate dehydrogenase kinase isoform 4 protein expression in starvation and after refeeding. Arch Biochem Biophys. 2001; 395: 246–252.[CrossRef][Medline]
[Order article via Infotrieve]
151. Wu P, Peters JM, Harris RA. Adaptive increase in pyruvate dehydrogenase kinase 4 during Starvation Is Mediated by Peroxisome Proliferator-Activated Receptor . Biochem Biophys Res Commun. 2001; 287: 391–396.[CrossRef][Medline]
[Order article via Infotrieve]
152. Young ME, Patil S, Ying J, Depre C, Singh Ahuja H, Shipley GL, Stepkowski SM, Davies PJA, Taegtmeyer H. Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor in the adult rodent heart. FASEB J. 2001; 15: 833–845.
This article has been cited by other articles:
 |
|
 |
|
  D. J. Chess, R. J. Khairallah, K. M. O'Shea, W. Xu, and W. C. Stanley A high-fat diet increases adiposity but maintains mitochondrial oxidative enzymes without affecting development of heart failure with pressure overload Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1585 - H1593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Djouadi, Y. Lecarpentier, J.-L. Hebert, P. Charron, J. Bastin, and C. Coirault A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy Cardiovasc Res, October 1, 2009; 84(1): 83 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Chaturvedi, P. Adhihetty, S. Shukla, T. Hennessy, N. Calingasan, L. Yang, A. Starkov, M. Kiaei, M. Cannella, J. Sassone, et al. Impaired PGC-1{alpha} function in muscle in Huntington's disease Hum. Mol. Genet., August 15, 2009; 18(16): 3048 - 3065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Rennison and D. R. Van Wagoner Impact of Dietary Fatty Acids on Cardiac Arrhythmogenesis Circ Arrhythm Electrophysiol, August 1, 2009; 2(4): 460 - 469. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Koitabashi, D. Bedja, A. L. Zaiman, Y. M. Pinto, M. Zhang, K. L. Gabrielson, E. Takimoto, and D. A. Kass Avoidance of Transient Cardiomyopathy in Cardiomyocyte-Targeted Tamoxifen-Induced MerCreMer Gene Deletion Models Circ. Res., July 2, 2009; 105(1): 12 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hibuse, N. Maeda, H. Nakatsuji, Y. Tochino, K. Fujita, S. Kihara, T. Funahashi, and I. Shimomura The heart requires glycerol as an energy substrate through aquaporin 7, a glycerol facilitator Cardiovasc Res, July 1, 2009; 83(1): 34 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bogazzi, F. Raggi, F. Ultimieri, D. Russo, A. D'Alessio, A. Manariti, S. Brogioni, L. Manetti, and E. Martino Regulation of cardiac fatty acids metabolism in transgenic mice overexpressing bovine GH J. Endocrinol., June 1, 2009; 201(3): 419 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Sack Innate Short-Circuiting of Mitochondrial Metabolism in Cardiac Hypertrophy: Identification of Novel Consequences of Enhanced Anaplerosis Circ. Res., March 27, 2009; 104(6): 717 - 719. [Full Text] [PDF]
|
|
|
|
|
|
H. Tsutsui, S. Kinugawa, and S. Matsushima Mitochondrial oxidative stress and dysfunction in myocardial remodelling Cardiovasc Res, February 15, 2009; 81(3): 449 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Bilsen, F. A. van Nieuwenhoven, and G. J. van der Vusse Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc Res, February 15, 2009; 81(3): 420 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Kane, K. A. Stevens, J. E. Fischer, M. Haghpassand, L. J. Royer, C. Aldinger, K. T. Landschulz, P. Zagouras, S. W. Bagley, W. Hada, et al. Molecular Characterization of Novel and Selective Peroxisome Proliferator-Activated Receptor {alpha} Agonists with Robust Hypolipidemic Activity in Vivo Mol. Pharmacol., February 1, 2009; 75(2): 296 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-K. Han, H.-S. Lee, H.-M. Yang, J. Hur, S.-I. Jun, J.-Y. Kim, C.-H. Cho, G.-Y. Koh, J. M. Peters, K.-W. Park, et al. Peroxisome Proliferator-Activated Receptor-{delta} Agonist Enhances Vasculogenesis by Regulating Endothelial Progenitor Cells Through Genomic and Nongenomic Activations of the Phosphatidylinositol 3-Kinase/Akt Pathway Circulation, September 2, 2008; 118(10): 1021 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Harmancey, C. R. Wilson, and H. Taegtmeyer Adaptation and Maladaptation of the Heart in Obesity Hypertension, August 1, 2008; 52(2): 181 - 187. [Full Text] [PDF]
|
|
|
|
|
|
J. H. Rennison, T. A. McElfresh, I. C. Okere, H. V. Patel, A. B. Foster, K. K. Patel, M. S. Stoll, P. E. Minkler, H. Fujioka, B. D. Hoit, et al. Enhanced acyl-CoA dehydrogenase activity is associated with improved mitochondrial and contractile function in heart failure Cardiovasc Res, July 15, 2008; 79(2): 331 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Chess and W. C. Stanley Role of diet and fuel overabundance in the development and progression of heart failure Cardiovasc Res, July 15, 2008; 79(2): 269 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Mazzatti, M. A. Smith, R. C. Oita, F.-L. Lim, A. J. White, and M. B. Reid Muscle unloading-induced metabolic remodeling is associated with acute alterations in PPAR{delta} and UCP-3 expression Physiol Genomics, July 1, 2008; 34(2): 149 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Scarpulla Transcriptional Paradigms in Mammalian Mitochondrial Biogenesis and Function Physiol Rev, April 1, 2008; 88(2): 611 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Page, R. Young, V. Iyer, G. Suzuki, M. Lis, L. Korotchkina, M. S. Patel, K. M. Blumenthal, J. A. Fallavollita, and J. M. Canty Jr Persistent Regional Downregulation in Mitochondrial Enzymes and Upregulation of Stress Proteins in Swine With Chronic Hibernating Myocardium Circ. Res., January 4, 2008; 102(1): 103 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fliegner, D. Westermann, A. Riad, C. Schubert, E. Becher, J. Fielitz, C. Tschope, and V. Regitz-Zagrosek Up-regulation of PPAR{gamma} in myocardial infarction Eur J Heart Fail, January 1, 2008; 10(1): 30 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Duda, K. M. O'Shea, B. Lei, B. R. Barrows, A. M. Azimzadeh, T. E. McElfresh, B. D. Hoit, W. J. Kop, and W. C. Stanley Dietary supplementation with {omega}-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload Cardiovasc Res, November 1, 2007; 76(2): 303 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Lopaschuk, C. D.L. Folmes, and W. C. Stanley Cardiac Energy Metabolism in Obesity Circ. Res., August 17, 2007; 101(4): 335 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. King, M. E. Young, J. Kerner, H. Huang, K. M. O'Shea, S. E. H. Alexson, C. L. Hoppel, and W. C. Stanley Diabetes or peroxisome proliferator-activated receptor {alpha} agonist increases mitochondrial thioesterase I activity in heart J. Lipid Res., July 1, 2007; 48(7): 1511 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Garcia-Roves, J. M. Huss, D.-H. Han, C. R. Hancock, E. Iglesias-Gutierrez, M. Chen, and J. O. Holloszy Raising plasma fatty acid concentration induces increased biogenesis of mitochondria in skeletal muscle PNAS, June 19, 2007; 104(25): 10709 - 10713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N. Finck and D. P. Kelly Peroxisome Proliferator-Activated Receptor {gamma} Coactivator-1 (PGC-1) Regulatory Cascade in Cardiac Physiology and Disease Circulation, May 15, 2007; 115(19): 2540 - 2548. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Neubauer The Failing Heart -- An Engine Out of Fuel N. Engl. J. Med., March 15, 2007; 356(11): 1140 - 1151. [Full Text] [PDF]
|
|
|
|
|
|
S. Gambert, C. Helies-Toussaint, and A. Grynberg Extracellular glycerol regulates the cardiac energy balance in a working rat heart model Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1600 - H1606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sharma, I. C. Okere, M. K. Duda, D. J. Chess, K. M. O'Shea, and W. C. Stanley Potential impact of carbohydrate and fat intake on pathological left ventricular hypertrophy Cardiovasc Res, January 15, 2007; 73(2): 257 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Handschin and B. M. Spiegelman Peroxisome Proliferator-Activated Receptor {gamma} Coactivator 1 Coactivators, Energy Homeostasis, and Metabolism Endocr. Rev., December 1, 2006; 27(7): 728 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. C. Okere, M. E. Young, T. A. McElfresh, D. J. Chess, V. G. Sharov, H. N. Sabbah, B. D. Hoit, P. Ernsberger, M. P. Chandler, and W. C. Stanley Low Carbohydrate/High-Fat Diet Attenuates Cardiac Hypertrophy, Remodeling, and Altered Gene Expression in Hypertension Hypertension, December 1, 2006; 48(6): 1116 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Morgan, M. P. Chandler, M. E. Young, T. A. McElfresh, T. A. Kung, J. H. Rennison, K.-Y. Tserng, B. D. Hoit, and W. C. Stanley Dissociation between gene and protein expression of metabolic enzymes in a rodent model of heart failure Eur J Heart Fail, November 1, 2006; 8(7): 687 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Javadov, D. M. Purdham, A. Zeidan, and M. Karmazyn NHE-1 inhibition improves cardiac mitochondrial function through regulation of mitochondrial biogenesis during postinfarction remodeling Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1722 - H1730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. An and B. Rodrigues Role of changes in cardiac metabolism in development of diabetic cardiomyopathy Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1489 - H1506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Hsieh, M. A. Choudhry, H.-P. Yu, T. Shimizu, S. Yang, T. Suzuki, J. Chen, K. I. Bland, and I. H. Chaudry Inhibition of cardiac PGC-1{alpha} expression abolishes ER{beta} agonist-mediated cardioprotection following trauma-hemorrhage FASEB J, June 1, 2006; 20(8): 1109 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Asai, K. Okumura, R. Takahashi, H. Matsui, Y. Numaguchi, H. Murakami, R. Murakami, and T. Murohara Combined therapy with PPAR{alpha} agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency Cardiovasc Res, June 1, 2006; 70(3): 566 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yamaguchi, S. Matsushita, K. Motojima, F. Hirose, and T. Osumi MLDP, a Novel PAT Family Protein Localized to Lipid Droplets and Enriched in the Heart, Is Regulated by Peroxisome Proliferator-activated Receptor {alpha} J. Biol. Chem., May 19, 2006; 281(20): 14232 - 14240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schupp, U. Kintscher, J. Fielitz, J. Thomas, R. Pregla, R. Hetzer, T. Unger, and V. Regitz-Zagrosek Cardiac PPAR{alpha} expression in patients with dilated cardiomyopathy Eur J Heart Fail, May 1, 2006; 8(3): 290 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Fosslien Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 347 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ikeuchi, H. Matsusaka, D. Kang, S. Matsushima, T. Ide, T. Kubota, T. Fujiwara, N. Hamasaki, A. Takeshita, K. Sunagawa, et al. Overexpression of Mitochondrial Transcription Factor A Ameliorates Mitochondrial Deficiencies and Cardiac Failure After Myocardial Infarction Circulation, August 2, 2005; 112(5): 683 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Lionetti, A. Linke, M. P. Chandler, M. E. Young, M. S. Penn, S. Gupte, C. d'Agostino, T. H. Hintze, W. C. Stanley, and F. A. Recchia Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure Cardiovasc Res, June 1, 2005; 66(3): 454 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Panagia, G. F. Gibbons, G. K. Radda, and K. Clarke PPAR-{alpha} activation required for decreased glucose uptake and increased susceptibility to injury during ischemia Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2677 - H2683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N. Petrashevskaya and A. Schwarz Peroxisome proliferator-activated receptor {beta}/{delta}: a new antihypertrophic drug target? Cardiovasc Res, March 1, 2005; 65(4): 770 - 771. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||